|
|
|
|
Vitrectomy Tips in Diabetics
American Diabetes Association Diabetes Statistics.http://www.diabetes.org/diabetes-statistics.jsp. Accessed September 1, 2008. Goodart R, Blankenship G. Panretinal photocoagulation influence on vitrectomy results for complications...
|
|
|
Intravitreal triamcinolone for intraocular inflammation and associated macular edema
Couch SM et al.- TA may be useful as an adjuvant in the treatment of uveitis and its associated macular edema, especially in patients resistant or intolerant to standard treatment. Intravitreal triamcinolone for intraocular...
|
|
|
iCo Therapeutics Oral Amphotericin B Poster at AAPS
iCo Therapeutics Inc.(TSX-V: ICO) is pleased to report that iCo-009, the company's oral Amphotericin B program, has been accepted for a poster presentation at the American Association of Pharmaceutical Scientist (AAPS) Meeting in Atlanta,...
|
|
|
Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients
_ Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.
|
|
|
Pharmacologic therapies for diabetic retinopathy and diabetic macular edema
Rechtman E et al.- Several biochemical mechanisms, including increased vascular endothelial growth factor production, protein kinase C beta activation, oxidative stress, and accumulation of intracellular sorbitol and advanced...
|
|
|
Distinct patterns of diabetic maculopathy seen on OCT
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Optical coherence tomography (OCT) is valuable in managing diabetic macular edema (DME), more so than...
|
|
|
Laser photocoagulation still standard of care for diabetic maculopathy
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo The Early Treatment Diabetic Retinopathy Study (ETDRS) laser is still the standard of care of diabetic maculopathy.
|
|
|
Consumer Group Calls for Ban on Rosiglitazone
WASHINGTON, Oct.30 -- The consumer advocacy organization Public Citizen has petitioned the FDA to ban the diabetes drug rosiglitazone (Avandia) because of its 'life-threatening risks that far outweigh its benefits.' The petition follows...
|
|
|
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2008
- pSivida Corp.(NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company, today announced financial results for the first quarter ended September 30, 2008. For the quarter ended September 30, 2008, the Company reported a consolidated net...
|
|
|
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2008
(NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company, today announced financial results for the first quarter ended September 30, 2008.For the quarter ended September 30, 2008, the Company reported a consolidated net loss of $471,000,...
|
|
|
pSivida Corp. Reports Results for the First Quarter Ended September 30, 2008
pSivida Corp.(NASDAQ:PSDV)(ASX:PVA)(FF:PV3), a drug delivery company, today announced financial results for the first quarter ended September 30, 2008. For the quarter ended September 30, 2008, the Company reported a consolidated net...
|
|
|
Can a VEGF Inhibitor Be Used to Effectively Treat Macular Edema Associated With Perfused Central Retinal Vein
_ Can a VEGF Inhibitor Be Used to Effectively Treat Macular Edema Associated With Perfused Central Retinal Vein.
|
|
|
Ranibizumab Is Effective in Diabetic Macular Oedema: Presented at AAO
-- Ranibizumab is effective in the treatment of diabetic macular oedema (DME), according to findings of the Ranibizumab for Edema of the Macula in Diabetes (READ)-2 trial.Peter A. Campochiaro, MD, Wilmer Eye Institute, Johns...
|
|
|
Intravitreal bevacizumab effective in refractory pseudophakic CME
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Intravitreal bevacizumab (Avastin, Genentech) shows promise as an alternative treatment modality for eyes with...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited (ASX: ELX), a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited , a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment...
|
|
|
Ellex Announces Six-Month Results on Retina Regeneration Therapy
ATLANTA, Nov.9 /PRNewswire/ -- Ellex Medical Lasers Limited , a global leader in the design and manufacture of ophthalmic laser and ultrasound systems, today announced the six-month clinical study results for the groundbreaking treatment...
|
|
|
The promise of VEGF inhibitors in ophthalmology: Opportunities
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Anti-vascular endothelial growth factor (VEGF) therapy has swept through ophthalmology over the past several years,...
|
|
|
AAO: Bevacizumab yields short-term VA increase in DME
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Bevacizumab (Avastin, Genentech) provided a visual acuity (VA) improvement that lasted 36 weeks following one...
|
|
|
Bevacizumab yields short-term VA increase in DME
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Bevacizumab (Avastin, Genentech) provided a visual acuity (VA) improvement that lasted 36 weeks following one...
|
|
|
AAO: Rapamycin safe for treating DME, finds phase I trial
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo A phase I trial of rapamycin (Sirolimus, Wyeth) indicated that the drug is safe and has biologic activity against...
|
|
|
Rapamycin safe for treating DME, finds phase I trial
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo A phase I trial of rapamycin (Sirolimus, Wyeth) indicated that the drug is safe and has biologic activity against...
|
|
|
Use of VEGF inhibitors studied in different retinal diseases
Source: Ophthalmology Times Meeting E-News Email|Print| Del.icio.us Digg Reddit Facebook |Save|License |Discuss On Sermo Anti-VEGF therapy has met with widespread acceptance in the ophthalmic community, and a recent poll of retinal...
|
|
|
AAO/SOE 2008: Ranibizumab Shows Efficacy in Phase 2 Trials of Diabetic Macular Edema
_ AAO/SOE 2008: Ranibizumab Shows Efficacy in Phase 2 Trials of Diabetic Macular Edema.
|
|
|
AAO/SOE 2008: Ranibizumab Shows Efficacy in Phase 2 Trials of Diabetic Macular Edema
_ AAO/SOE 2008: Ranibizumab Shows Efficacy in Phase 2 Trials of Diabetic Macular Edema.
|
